| 000 | 02529 a2200757 4500 | ||
|---|---|---|---|
| 005 | 20250517191730.0 | ||
| 264 | 0 | _c20180904 | |
| 008 | 201809s 0 0 eng d | ||
| 022 | _a1432-1041 | ||
| 024 | 7 |
_a10.1007/s00228-017-2393-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhong, Zhixiong | |
| 245 | 0 | 0 |
_aEffect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical pharmacology _cApr 2018 |
||
| 300 |
_a423-431 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAcute Coronary Syndrome _xdiagnostic imaging |
| 650 | 0 | 4 |
_aAdenosine _xanalogs & derivatives |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAsian People _xgenetics |
| 650 | 0 | 4 | _aChi-Square Distribution |
| 650 | 0 | 4 | _aChina |
| 650 | 0 | 4 | _aClinical Decision-Making |
| 650 | 0 | 4 | _aClopidogrel |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2C19 _xgenetics |
| 650 | 0 | 4 | _aDrug-Eluting Stents |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Frequency |
| 650 | 0 | 4 | _aGenetic Predisposition to Disease |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 | _aHeterozygote |
| 650 | 0 | 4 | _aHomozygote |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xcomplications |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aLogistic Models |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyocardial Infarction _xblood |
| 650 | 0 | 4 |
_aPercutaneous Coronary Intervention _xadverse effects |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 | _aPharmacogenomic Variants |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 | _aPrecision Medicine |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aStroke _xblood |
| 650 | 0 | 4 | _aTicagrelor |
| 650 | 0 | 4 |
_aTiclopidine _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHou, Jingyuan | |
| 700 | 1 | _aZhang, Qifeng | |
| 700 | 1 | _aLi, Bin | |
| 700 | 1 | _aLi, Cunren | |
| 700 | 1 | _aLiu, Zhidong | |
| 700 | 1 | _aYang, Min | |
| 700 | 1 | _aZhong, Wei | |
| 700 | 1 | _aHe, Xuebo | |
| 700 | 1 | _aWu, Hesen | |
| 700 | 1 | _aZhong, Miaocai | |
| 700 | 1 | _aZhao, Pingsen | |
| 773 | 0 |
_tEuropean journal of clinical pharmacology _gvol. 74 _gno. 4 _gp. 423-431 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00228-017-2393-1 _zAvailable from publisher's website |
| 999 |
_c27891454 _d27891454 |
||